Ryvu Therapeutics S.A.
RVU.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.40 | 1.17 | -1.79 | -0.11 |
| FCF Yield | -15.21% | -6.81% | 1.33% | -6.24% |
| EV / EBITDA | -8.32 | -15.26 | -12.33 | -15.79 |
| Quality | ||||
| ROIC | -45.07% | -30.22% | -19.20% | -53.20% |
| Gross Margin | 74.89% | 62.54% | 55.14% | -22.69% |
| Cash Conversion Ratio | 1.16 | 0.92 | -0.25 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.19% | 61.20% | 36.04% | -35.95% |
| Free Cash Flow Growth | -53.64% | -832.33% | 117.23% | -55.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | 0.70 | 1.52 | 1.19 |
| Interest Coverage | -32.06 | -1,040.70 | -72.01 | -234.80 |
| Efficiency | ||||
| Inventory Turnover | 16.18 | 8.29 | 9.90 | 7.01 |
| Cash Conversion Cycle | -460.21 | -365.59 | -179.38 | 124.28 |